Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Desmoid Tumors Market size was over USD 3.2 billion in 2024 and is estimated to reach USD 8.4 billion by the end of 2037, expanding at a CAGR of 7.6% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of desmoid tumors is evaluated at USD 3.4 billion.
Desmoid tumors also known as aggressive fibromatosis are rare soft-tissue tumors that are considered by infiltrative growth and can affect organs and adjacent structures, resulting in significant clinical burden impacting patients’ health-related quality of life. According to an article published by NLM in July 2023, the incidence rate of the condition is approximately ranges between 3 to 5 cases per million person-years. In addition, 63% of patients suffer from chronic pain leading to 73% of cases of sleep disturbance, 46% of irritability, and 15% of anxiety. To combat this, there are no appropriate treatments available, however latest innovations paved the way for the development of new treatments which is driving the desmoid tumors market growth.
The continuous research and development in the pharmaceutical industry to manufacture and produce drugs to overcome desmoid tumors which are amplifying the desmoid tumors market. Moreover, there is ongoing trial analysis to make these drugs cost-effective, especially for developing nations. In this regard, an analytical study was conducted on 84 patients for the progression-free survival (PFS) rate of sorafenib, as published by NLM in February 2022. The study revealed the present medicare payer’s pricing of the drug which was USD 309 per day based on 400 mg/day dosage. Besides, the absolute risk reduction (ARR) was also evaluated based on the response rate in 1 year and 2 years, thus improving the PFS rate in patients with desmoid tumors.
Sorafenib Evaluation based on ARR, RECIST, and NNT
|
Evaluation Types |
Rate |
Cost |
|
ARR |
17.5% |
USD 1,285,052 for 2 years |
|
RECIST |
14.7% (1 year) |
USD 766,938 |
|
NNT (number-needed-to-treat) |
6.8% (1 year) 6.9% (2 years) |
USD 1,556,433 |
Source: NLM February 2022
Desmoid Tumors Sector: Growth Drivers and Challenges
Growth Drivers
- Availability of novel treatment options: At present, there is no provision of standard treatment options that can undergo unprompted regression in up to 20% of patients, as stated in the January 2024 NLM article. However, recently introduced gamma-secretase inhibitors have displayed clinical benefits for patients with desmoid tumors. In addition, cryoablation is relatively the latest which is currently under investigation to ensure a standard treatment facility for patients suffering from the condition. Therefore, ongoing research and development for launching novel therapies is highly driving the desmoid tumors market growth.
- Increase in technology advancements: The aspect of contributions made by device organizations to make innovations in medical-based technologies are another driving boosting the desmoid tumors market. For instance, in November 2020, Profound Medical Corp. notified that its Sonalleve has received the U.S. FDA approval. The approval was provided under the Humanitarian Device Exemption (HDE), suitable and effective for the treatment of osteoid osteoma. Therefore, such innovations by companies and approval by administrative bodies are readily bolstering the market internationally.
Challenges
- High treatment expenditure: The increase in the pricing of treatment options is posing a huge challenge for the desmoid tumors market. The low-income nations are readily devoid of the latest treatments owing to low-to-moderate income levels in comparison to those of developed nations. Besides, the drug availability for the treatment of the condition is also hindering the market growth due to high pricing strategy. This ultimately results in non-treatment of the condition which leads to adverse health disorders, which in turn further results in loss of lives, especially for the elderly population.
- Side-effects of therapies: Patients undergoing cancer treatments constitute a risk of developing side effects on a long-term basis, which is yet another restraint for the desmoid tumors market. Common side effects include fatigue, pain, anemia, nausea, mouth problems, dietary issues as well as nail, skin, and hair problems. Besides, certain chemotherapy drugs damage healthy cells alongside getting rid of cancer cells. For instance, blood-forming cells, cells present in the digestive and reproductive systems, and skin cells are readily at risk during the therapy process, thus a barrier in the ailment of desmoid tumors.
Desmoid Tumors Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.6% |
|
Base Year Market Size (2024) |
USD 3.2 billion |
|
Forecast Year Market Size (2037) |
USD 8.4 billion |
|
Regional Scope |
|
Desmoid Tumors Segmentation
Drug Type (Chemotherapy, Non-steroidal anti-inflammatory drugs (NSAIDs), Targeted Therapy, Hormone Therapy)
Based on the drug type segment is projected to dominate desmoid tumors market share of around 45.7% by the end of 2037. Chemotherapy can relieve symptoms and signs of cancer by combating certain cancer cells. As per the November 2021 NLM article, a comparative study was conducted between 905 chemotherapy-exposed and chemotherapy-naïve patients. The overall survival rate was 76.3% versus 69.3% based on 18 months, and 61.6% versus 54.3% in case of 30 months. Therefore, the implementation of chemotherapy is the most essential and potential therapeutic option which is driving the market expansion.
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
The hospital pharmacy segment is expected to influence the desmoid tumors market at a considerable rate during the forecast timeline. The management of patients by a multidisciplinary team, shared decision-making, and treatment selection are a few factors responsible for the growth of the segment. As per a review-based study conducted by NLM in January 2025, 8 studies with the inclusion of hospital pharmacists were reviewed based on their role in managing cell and gene therapy (CGT) and advanced therapy medicinal products (ATMPs). Their common interventions centered around the administration, prescription, and monitoring of medicine usage, thus driving the expansion of the segment.
Our in-depth analysis of the global desmoid tumors market includes the following segments:
|
Drug Type |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportDesmoid Tumors Industry - Regional Synopsis
North America Market Analysis
North America desmoid tumors market is predicted to capture revenue share of around 41.9% by the end of 2037. The region is subjected to innovation for the development of the latest and advanced technologies for the treatment of cancer. According to the 2025 American Oncology Institute report, Bravos, TrueBeam, Ethos therapy combined with IDENTIFY, Halcyon, Clinac iX, Gamma Medplus iX, Da Vinci X System, PET-CT, SPECT-CT, MRI 1.5 Tesla, and Computed Tomography are a few technologies available in the region. Out of these, TrueBeam delivers accurate image-guided treatments with 60% rapid 3-D anatomical image generation with 25% less usage of X-ray doses.
The U.S. desmoid tumors market has been gaining traction due to the frequent occurrence of the condition among the population. As per the May 2023 NLM report, approximately 1,650 people in the country are diagnosed with desmoid tumors every year. This rare disease condition majorly affects young people, but people of any age can be prone to desmoid tumors, which is also referred to as aggressive fibromatosis. However, with advanced medical facilities and the introduction of the latest technological devices, it has become easier for healthcare professionals to detect and combat the condition among the population.
The desmoid tumors market in Canada is witnessing significant growth owing to the provision of investments by the government. For instance, as per the May 2024 National Organization for Rare Disorders report, there has been the launch of two regional patient registries within its IAMRARE Program. Therefore, this resulted in the recognition of approved treatments to aid at least 95% of rare diseases. In this regard, the government of Canada committed an investment of USD 1.5 billion over five years as part of its National Strategy for Drugs for Rare Diseases. This investment is intended to advance the development of gene therapies for rare diseases, thus positively driving the market in the country.
APAC Market Statistics
The desmoid tumors market in APAC is the fastest-growing region and is poised to witness lucrative growth during the forecast timeline. Factors such as increased patient pool along with the development of advanced healthcare technology are readily driving the market growth in the region. In March 2025, a study was published by Esmo Open regarding 57 healthcare and oncology indicators and their performance across 47 nations in the region. For instance, there is the provision of compulsory national health insurance schemes financed primarily by premiums or taxes, as well as government subsidies in Australia, Japan, and South Korea, catering to the upliftment of the market in the region.
The desmoid tumors market in India is expecting substantial growth since there have been medical developments through research to detect symptoms of the condition. According to a clinical study published by the ecancer organization in June 2024, the presence of occurrence of rare diseases resulted in the development of questionnaires to assess knowledge, attitude, and practice (KAP) among healthcare professionals regarding the condition. The E-Delphi method was utilized for the assessment of KAP to evaluate the condition with the provision of 22 open-ended questions developed by research groups in the country. Therefore, this is a useful strategy for medical providers to identify and provide solutions to overcome the spread of the.
The desmoid tumors market in China is gaining exposure owing to its occurrence in the abdominal cavity and wall among the regional population. As per the December 2020 NLM article, 343 patients from China-based hospitals were considered for a clinical study and all of them undertook surgical resection and were pathologically diagnosed with desmoid tumors. The local recurrence rate was 8% and the study revealed that only 3% of patients with abdominal wall desmoid tumors had local recurrence during follow-up. However, the local recurrence rate of patients with intra-abdominal conditions was 23.1% and the tumor size ranged between 5 cm to 10 cm.
Companies Dominating the Desmoid Tumors Landscape
- Amneal Pharmaceuticals LLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Assertio Holdings, Inc.
- Alembic Pharmaceuticals Limited
- Aprazer
- Ayala Pharmaceuticals
- Abbott
- Apotex Inc.
- Bayer AG
- Dr. Reddy’s Laboratories Ltd.
- Endo International plc
- Getwell Pharmaceuticals
- Horizon Therapeutics Plc
- Hikma Pharmaceuticals PLC
- Iterion Therapeutics, Inc.
- Immunome, Inc.
- Lupin
- Mayne Pharma Group Limited
- Mylan N.V.
- Novartis AG
- Sun Pharmaceuticals Industries Ltd.
- SpringWorks Therapeutics Inc.
- Zydus Lifesciences
Companies dominating the desmoid tumors market are gaining rapid exposure due to the aspect of mergers and acquisitions for the provision of treatment solutions to patients globally. For instance, in February 2024, Immunome, Inc. entered into a decisive asset purchase agreement with Ayala Pharmaceuticals, Inc. to acquire AL102 and related drug candidate AL101 from Ayala. Based on the agreement terms, Immunome will invest USD 20 million in cash on Ayala and USD 30 million in Immunome common stock at the closing and will pay up to an additional USD 37.5 million in development and commercial milestone payments.
Furthermore, AL102 is a tentative small molecule gamma-secretase inhibitor presently being evaluated in the randomized Phase 3 RINGSIDE international trial for the treatment of desmoid tumors. It is a potential once-daily oral treatment to aid patients suffering the tumor condition which is more effective than OGSIVEO. Besides, the Phase 2 study trial demonstrated clinically meaningful anti-tumor activity across multiple parameters. It displayed high objective response rates including 75% of evaluable patients in the 1.2 mg once-daily arm, thus a positive outlook for the desmoid tumors market to expand globally.
Here's the list of some key players:
In the News
- In January 2025, SpringWorks Therapeutics, Inc. declared the net product revenue for OGSIVEO (nirogacestat) of which it received the U.S. FDA approval in November 2023. The company achieved USD 61.5 million and USD 172.0 million in its fourth quarter with the availability of the drug in the market.
- In June 2022, Iterion Therapeutics, Inc. notified results from a Phase 1 study of tegavivint in patients with desmoid tumors. This will be featured in a poster presentation and discussion session at the 2022 American Society of Clinical Oncology Annual Meeting.
Author Credits: Radhika Pawar
- Report ID: 7331
- Published Date: Mar 11, 2025
- Report Format: PDF, PPT
